Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia.

Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Abstract Text:

    taku kokuboTaku Kokubo,hisashi uchidaHisashi Uchida,eric t choiEric T Choi,

    Although major advances have been made in the prevention and treatment of restenosis following coronary and peripheral interventions, the persistent complications of thrombosis and reintervention remain a mainstay for repeat hospitalizations in this patient population. For many years, a ubiquitous cell surface receptor called alpha(v)beta(3) integrin was the target of investigators in the prevention of restenosis because its interaction with the extracellular matrix was believed to coordinate the migration of smooth muscle cells (SMCs) from the media to the intima, the seminal event in the formation of intimal occlusive lesion. After the publication of uniformly positive animal studies demonstrating that alpha(v)beta(3) integrin blockade led to a significant reduction in new intimal (neointimal) lesion formation, early clinical trials supported the association of avoidance of target lesion revascularization and the use of antagonists to the SMC integrin alpha(v)beta(3) and its related platelet integrin alpha(IIb)beta(3). However, a series of clinical trials subsequently demonstrated that these antagonists did not necessarily prevent revascularizations by inhibiting intimal hyperplasia per se. Additional animal studies subsequently showed that, indeed, in the setting of pre-existing SMCs in the intimal lesion (ie, atherosclerotic plaque, fatty streaks), inhibiting SMC migration by way of beta(3) integrin blockade was an ineffective approach in the prevention of intimal hyperplasia and restenosis. However, given the wealth of basic and clinical information on the alpha(v)beta(3) integrin and its antagonists, we discuss in this article our new approach to this old solution by targeting a new clinical problem of early failure arteriovenous access for hemodialysis. Given the uniqueness of arteriovenous access in that there are essentially no significant atherosclerotic lesions in the artery and vein prior to the anastomosis, the seminal event of the migration of SMCs from the media to the neointima could by targeted once again with beta(3) integrin antagonists.

    Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Publishing Authors By Initials

    t kokuboT Kokubo,h uchidaH Uchida,et choiET Choi,

    For similar surgical procedures, operative: cardiovascular surgical procedures: vascular surgical procedures research abstracts see: surgical procedures, operative: cardiovascular surgical procedures: vascular surgical procedures research

    PUBMED ID PMID:

    MEDLINE DATE:

    Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Journal Published:

    PUBLICATION TYPE: Review

    Journal: Journal of vascular surgery : official publication

    VOLUME: 45 Suppl A

    Page Numbers: A33-8

    Journal Abbreviation: J. Vasc. Surg.

    ISSN: 0741-5214

    DAY: 3

    MONTH: Jun

    YEAR: 2007

    Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8407742

    Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Keywords Mesh Terms:

    KEYWORDS: Vascular Surgical Procedures

    MESH TERMS: adverse effects

    Chemical & Substance for Abstract: Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. Information

    Substance Name: Integrin alphaVbeta3

    Registry Number: 0

    Grant and Affiliation Information for Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia.

    AFFILIATION: Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NHLBI

    GRANT: K08 HL068119-01A1

    ACRONYM: HL

    MEDLINETA: J Vasc Surg

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Integrin alphavbeta3 as a target in the prevention of neointimal hyperplasia Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News